Articles

Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens

Abstract

In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy - radiotherapy.

Joseph M. Connors, Clinical Manifestations and Natural History of Hodgkin’s Lymphoma, Cancer J 2009;15: 124–128)

Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.

Bodis S, Henry-Amar M, Bosq J, et al. Late relapse in early-stage Hodgkin’s disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J ClinOncol. 1993;11:225–232.

Connors JM. Hodgkin’s lymphoma: the hazards of success. J ClinOncol. 2003;21:3388 –3390.

Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J ClinOncol. 2003;21:3431 3439.

Vose JM, Constine LS, Sutcliffe SB. Other complications of the treatment of Hodgkin lymphoma. In: Hoppe RT, Mauch PM, Armitage JO, et al, eds. Hodgkin Lymphoma. Philadelphia: Wolters Kluwer; 2007:383–392.

Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006.

NgAK, Mauch PM. Late effects of Hodgkin’s disease and its treatment. Cancer J. 2009;15(2):164-168.

KilickapS,Barista I, Ulger S, Celik I, Selek U, Yıldız F, et al. Clinical Features and Prognostic Factors of Hodgkinʼs Lymphoma: a Single Center Experience. BALKAN Medical Journal 2013;30:178-185.

Al-Shemmari S, Al-Humood S, Ameen R, Kamlesh S, Nemec J, Varghese A. Hodgkinʼs Disease: Kuwait Experience. Med Principles and Practice 2004;13:201-205.

Gocheva L, Koleva I. long term out come of treatment for Hodgkinʼs Disease. The university Hospital Sofia Experience. KlinOnkol 2010;23(1):34-42.

Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, et al. Long term Follow up Analysis of HD9601 Trial Comparing ABVD Versus MOPP/EBV/CAD in patients with newly Diagnosed Advanced- Stage HodgkinʼsLymphoma:A study from the intergruppoitalianolinfomi Journal of Clinical Oncology 2012;29(32):4227-33.

Coskun HS, Er O, Eser B, et al. Early Stage Hodgkinʼs Lymphoma Disease:Experiences of Erciyes University. Erciyes Med J 2002;24:120-5

KilickapS,Barista I, Ulger S, Celik I, Selek U, Yıldız F, et al. Long-term complications in Hodgkin’s lymphoma survivors.Tumori a Journal of Experimental and Clinical Oncology 2012;98(5):601-6.

Townsend w, Linch D. Hodgkinʼs Lymphoma in adults. Lancet 2012;380:836-47.

Christina Clarke, Cynthia O’Malley, and Sally Glaser, Hodgkin Lymphoma, National Cancer Institute , SEER Survival Monograph, 224-234,2002

Files
IssueVol 8, No 2 (2014) QRcode
SectionArticles
Keywords
Chemotherapy Hodgkin Second malignancy Survival
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ahmadzadeh A, Yekaninejad MS, Jalili MH, Bahadoram M, Efazat M, Seghatoleslami M, Yazdi F, Mahdipour M, Valizadeh A, Saki N. Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin’s Lymphoma Patients with Chemotherapy Regimens. Int J Hematol Oncol Stem Cell Res. 1;8(2):21-26.